Trial Profile
Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Arimoclomol (Primary)
- Indications Inclusion body myositis
- Focus Registrational; Therapeutic Use
- Sponsors Orphazyme
- 26 Apr 2022 Results assessing efficacy and safety/tolerability of arimoclomol , presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 01 Apr 2021 Topline results published in the CytRx Corporation media release.
- 29 Mar 2021 According to an Orphazyme media release, the analysis of the data is continuing and complete findings from the study will be shared in a future scientific forum.